bioMérieux S.A.
BMXMFOTCHealthcare● Active
$84.00
+$0.69(+0.83%)
Market Cap$9.9B
P/E Ratio—
52W High$152
52W Low$77.38
bioMérieux S.A. (BMXMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BMXMF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 27, 2026EPS Actual
$2.35
Est. $2.50 · -6.0%
Revenue
$2.38B
Est. $2.49B · -4.4%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 27, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
BMXMF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | $2.61 | — | — | — | $1.17B | — |
| ▼ Q1 FY2026 | Feb 27, 2026 | $2.50 | $2.35 | -6.0% | $2.38B | $2.49B | -4.4% |
| ▼ Q2 FY2025 | Jun 30, 2025 | $2.55 | $1.59 | -37.6% | $2.41B | $2.44B | -1.4% |
| ▼ Q4 FY2024 | Dec 31, 2024 | $2.23 | $1.89 | -15.3% | $2.15B | $2.13B | +1.1% |
| — Q2 FY2024 | Jun 29, 2024 | — | $1.95 | — | $2.04B | $2.01B | +1.8% |
| — Q4 FY2023 | Dec 30, 2023 | — | $1.81 | — | $2.09B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $1.49 | — | $1.93B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $2.04 | — | $2.08B | — | — |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
$2.61
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 27, 2026Miss
EPS Actual
$2.35
EPS Est.
$2.50
EPS Surpr.
-6.0%
Revenue
$2.38B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
$1.59
EPS Est.
$2.55
EPS Surpr.
-37.6%
Revenue
$2.41B
Q4 FY2024
Dec 31, 2024Miss
EPS Actual
$1.89
EPS Est.
$2.23
EPS Surpr.
-15.3%
Revenue
$2.15B
Q2 FY2024
Jun 29, 2024
EPS Actual
$1.95
EPS Est.
—
EPS Surpr.
—
Revenue
$2.04B
Q4 FY2023
Dec 30, 2023
EPS Actual
$1.81
EPS Est.
—
EPS Surpr.
—
Revenue
$2.09B
Q2 FY2023
Jun 30, 2023
EPS Actual
$1.49
EPS Est.
—
EPS Surpr.
—
Revenue
$1.93B
Q4 FY2022
Dec 31, 2022
EPS Actual
$2.04
EPS Est.
—
EPS Surpr.
—
Revenue
$2.08B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $1.0B | $1.0B | $1.0B | 1 |
| Q1 FY2026 | $0.9B | $0.9B | $1.0B | 2 |
| Q4 FY2025 | $1.0B | $1.0B | $1.0B | 1 |
| Q3 FY2025 | $0.8B | $0.8B | $0.9B | 2 |
| Q2 FY2025 | $0.8B | $0.8B | $0.8B | 1 |
| Q1 FY2025 | $1.0B | $1.0B | $1.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 27, 2026 | -6.0% | $109.61 | $115.00 | +4.92% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -37.6% | $142.45 | $142.45 | +0.00% |
| ▼ Q4 FY2024 | Dec 31, 2024 | -15.3% | $106.19 | $106.19 | +0.00% |
| — Q2 FY2024 | Jun 29, 2024 | — | $96.50 | $96.50 | +0.00% |
| — Q4 FY2023 | Dec 30, 2023 | — | $108.50 | $108.54 | +0.04% |
| — Q2 FY2023 | Jun 30, 2023 | — | $98.33 | $98.33 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $106.00 | $106.00 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $94.43 | $94.43 | +0.00% |
Q1 FY2026+4.92%
Report Date
Feb 27, 2026
EPS Beat/Miss
-6.0%
Price Before
$109.61
Price After
$115.00
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
-37.6%
Price Before
$142.45
Price After
$142.45
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
-15.3%
Price Before
$106.19
Price After
$106.19
Q2 FY2024+0.00%
Report Date
Jun 29, 2024
EPS Beat/Miss
—
Price Before
$96.50
Price After
$96.50
Q4 FY2023+0.04%
Report Date
Dec 30, 2023
EPS Beat/Miss
—
Price Before
$108.50
Price After
$108.54
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$98.33
Price After
$98.33
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$106.00
Price After
$106.00
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$94.43
Price After
$94.43
Avg Miss Reaction+1.64%
Beat Rate0 / 8 quarters
Largest Move+4.92% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BMXMF ends December
bioMérieux S.A. (BMXMF) most recently reported earnings on February 27, 2026 for Q1 FY2026, posting EPS of $2.35 — missing the analyst consensus of $2.50 by -6.0%. The next BMXMF earnings date is expected around September 1, 2026.
Each quarter, investors track BMXMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BMXMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BMXMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BMXMF earnings · 5 questionsbioMérieux S.A.'s next earnings report is expected around September 1, 2026. BMXMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BMXMF historically reports after market close (AMC).
BMXMF earnings datewhen is BMXMF earningsBMXMF next earnings datewhen does BMXMF report earningsBMXMF earnings calendar
▸ Source: FMP · bioMérieux S.A. SEC filings · US GAAP · bioMérieux S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026